The latest report by IMARC Group, titled “Viral Vector Manufacturing Market Report by Type (Adenoviral Vectors, Adeno-associated Viral Vectors, Lentiviral Vectors, Retroviral Vectors, and Others), Disease (Cancer, Genetic Disorders, Infectious Diseases, and Others), Application (Gene Therapy, Vaccinology), End User (Pharmaceutical and Biopharmaceutical Companies, Research Institutes), and Region 2025-2033,” finds that the global viral vector manufacturing market size reached USD 1,469.6 Million in 2024. A viral vector is a tool used to deliver genetic material into cells. This process is performed inside a living organism (in vivo) or in cell culture (in vitro). It is widely used in gene and cell therapy to replace defective genes with functional genes. Besides this, viral vectors are also utilized to treat different diseases, such as heart defects, metabolic diseases, neurodegenerative disorders, and oncolytic therapies, to target and kill tumor cells. In recent years, there has been a significant rise in viral vector manufacturing due to the rising prevalence of genetic disorders.
Global Viral Vector Manufacturing Market Trends:
The market is primarily driven by the rising number of cancer patients across the globe as viral vectors are used in suicide gene therapy, oncolytic virotherapy, anti-angiogenesis, and therapeutic gene vaccines to treat a wide range of cancers. In addition, the increasing number of clinical studies undertaken on viral vectors is contributing to the market growth. Besides this, as viral vectors are efficient carriers of virus-disabling sequences, they are widely used to deliver HIV-inhibiting transgenes to human hematopoietic stem cells (HSCs). This, coupled with the rising utilization of viral vectors in novel drug delivery, is positively influencing the market growth. Furthermore, the introduction of advanced therapies, the rising number of gene therapy-based research and development (R&D) activities, and the increasing manufacturing capacities of key players are anticipated to propel the market growth. Looking forward, IMARC Group expects the market value to reach USD 8,512.2 Million by 2033, exhibiting a CAGR of 21.6% during the forecast period (2025-2033).
Market Summary:
Report Features | Details |
---|---|
Base Year of the Analysis | 2024 |
Historical Period | 2019-2024 |
Forecast Period | 2025-2033 |
Units | Million USD |
Segment Coverage | Type, Disease, Application, End User, Region |
Region Covered | Asia Pacific, Europe, North America, Latin America, Middle East and Africa |
Countries Covered | United States, Canada, Germany, France, United Kingdom, Italy, Spain, Russia, China, Japan, India, South Korea, Australia, Indonesia, Brazil, Mexico |
Companies Covered | Cognate BioServices Inc. (Charles River Laboratories International Inc.), F. Hoffmann-La Roche AG, FinVector Oy, FUJIFILM Holdings Corporation, Kaneka Eurogentec S.A. (Kaneka Corporation), Lonza Group AG, Merck KGaA, Oxford Biomedica plc, REGENXBIO Inc., Sanofi S.A., Thermo Fisher Scientific Inc. and uniQure N.V. |
Customization Scope | 10% Free Customization |
Post-Sale Analyst Support | 10-12 Weeks |
Delivery Format | PDF and Excel through Email (We can also provide the editable version of the report in PPT/Word format on special request) |
About Us:
IMARC Group is a leading market research company that offers management strategy and market research worldwide. We partner with clients in all sectors and regions to identify their highest-value opportunities, address their most critical challenges, and transform their businesses.
IMARC’s information products include major market, scientific, economic and technological developments for business leaders in pharmaceutical, industrial, and high technology organizations. Market forecasts and industry analysis for biotechnology, advanced materials, pharmaceuticals, food and beverage, travel and tourism, nanotechnology and novel processing methods are at the top of the company’s expertise.
Contact Us:
IMARC Group
134 N 4th St.
Brooklyn, NY 11249, USA
Email: Sales@imarcgroup.com
Americas:- +1 631 791 1145 | Africa and Europe :- +44-753-713-2163 | Asia: +91-120-433-0800